Your browser is no longer supported. Please, upgrade your browser.
Settings
ALXN Alexion Pharmaceuticals, Inc. daily Stock Chart
ALXN [NASD]
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E60.88 EPS (ttm)2.92 Insider Own0.80% Shs Outstand225.81M Perf Week-5.57%
Market Cap40.14B Forward P/E29.96 EPS next Y5.93 Insider Trans-5.77% Shs Float198.79M Perf Month8.50%
Income588.90M PEG3.95 EPS next Q1.38 Inst Own97.90% Short Float5.48% Perf Quarter-1.39%
Sales2.27B P/S17.70 EPS this Y156.70% Inst Trans0.20% Short Ratio5.17 Perf Half Y-5.19%
Book/sh17.64 P/B10.08 EPS next Y18.80% ROA14.70% Target Price220.00 Perf Year12.79%
Cash/sh8.53 P/C20.85 EPS next 5Y15.40% ROE18.40% 52W Range150.06 - 203.30 Perf YTD-3.93%
Dividend- P/FCF77.48 EPS past 5Y14.90% ROI19.50% 52W High-12.56% Beta0.58
Dividend %- Quick Ratio4.60 Sales past 5Y42.00% Gross Margin90.70% 52W Low18.46% ATR5.04
Employees2273 Current Ratio4.90 Sales Q/Q5.90% Oper. Margin36.40% RSI (14)52.68 Volatility2.68% 2.78%
OptionableYes Debt/Eq0.01 EPS Q/Q-43.00% Profit Margin26.00% Rel Volume1.12 Prev Close184.45
ShortableYes LT Debt/Eq0.00 EarningsJul 23 BMO Payout0.00% Avg Volume2.11M Price177.76
Recom1.80 SMA202.49% SMA503.89% SMA200-0.43% Volume2,370,047 Change-3.63%
May-07-15Upgrade Nomura Neutral → Buy
May-07-15Reiterated Brean Capital Buy $215 → $213
Jan-30-15Reiterated Stifel Buy $230 → $236
Jan-08-15Reiterated UBS Buy $220 → $213
Apr-25-14Reiterated Stifel Buy $219 → $220
Mar-11-14Reiterated UBS Buy $185 → $202
Mar-11-14Reiterated Stifel Buy $207 → $219
Mar-06-14Reiterated Barclays Overweight $181 → $193
Feb-10-14Reiterated Deutsche Bank Buy $125 → $205
Jan-31-14Reiterated Stifel Buy $138 → $207
Jan-31-14Reiterated Canaccord Genuity Buy $161 → $200
Jan-31-14Reiterated Barclays Overweight $141 → $181
Jan-30-14Reiterated Brean Capital Buy $142 → $200
Jan-10-14Reiterated Barclays Overweight $127 → $141
Jan-06-14Reiterated UBS Buy $130 → $150
Jan-06-14Reiterated Canaccord Genuity Buy $138 → $161
Oct-25-13Reiterated Stifel Buy $131 → $138
Oct-25-13Reiterated Barclays Overweight $121 → $127
Jul-26-13Reiterated Barclays Overweight $118 → $121
Apr-26-13Reiterated UBS Buy $120 → $123
Jun-29-15 04:25PM  Alexion's Strensiq and Kanuma Get Positive CHMP Opinions - Analyst Blog
Jun-26-15 07:13AM  Europe gives green light to new Novartis, Alexion drugs Reuters
07:11AM  Alexion Receives CHMP Positive Opinions for Strensiq (asfotase alfa) and Kanuma (sebelipase alfa) in the European Union Business Wire
Jun-23-15 01:30PM  This Firm Controls An Incredibly Profitable Niche
08:16AM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material
06:30AM  Alexion Completes Acquisition of Synageva Business Wire
Jun-22-15 06:30AM  Alexion Accepts Shares of Synageva BioPharma Corp. Tendered Into Exchange Offer Business Wire
Jun-20-15 09:35AM  5 Unusual Movers in the S&P 500 at 24/7 Wall St.
Jun-19-15 07:50AM  Summer is for healthcare
Jun-16-15 08:02AM  Top Health Care Funds: Can Outperformance Continue? at Investor's Business Daily
Jun-12-15 12:38PM  Alnylam Reports Data on Potential Alexion Rival Drug at Investor's Business Daily
Jun-11-15 07:01AM  Gaps in drugs pipelines spark a flurry of takeover activity at Financial Times
03:38AM  Edited Transcript of ALXN presentation 10-Jun-15 3:40pm GMT
Jun-10-15 07:47AM  Short-term bulls targeting Alexion +6.82%
Jun-04-15 02:57PM  Alexion: Don't Fear the Competition at Barrons.com
Jun-02-15 10:00AM  Alexion to Present at Investor Conferences Business Wire
May-29-15 04:20PM  Alexion and Synageva Announce Early Termination of Hart-Scott-Rodino Waiting Period for Alexions Pending Acquisition of Synageva Business Wire
May-27-15 03:05PM  The Synageva BioPharmaAlexion Deal Spread Has Some Hair on It
May-22-15 03:24PM  Summer stock picks
02:45PM  A Beautiful Biotech Summer? at Barrons.com
May-21-15 03:57PM  Pall-Danaher Transaction: What You Should Know about Danaher
03:57PM  Pall-Danaher Transaction: An Overview of Pall
May-20-15 01:52PM  Achillion Dives As J&J Hep C Deal Chills Buyout Buzz at Investor's Business Daily
09:46AM  Gilead Sciences: Little Risk From Achillion's Hep-C Partnership With J&J at Barrons.com
08:25AM  Do R&D Costs Matter When It Comes To Drug Pricing? at Forbes
May-14-15 11:06AM  Should You Set Up the Synageva BioPharmaAlexion Spread?
07:54AM  Platinum picks for your portfolio
May-13-15 03:07PM  Alexion Pharmaceuticals: A Focus on Treating Rare Disorders
May-12-15 05:21PM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
04:25PM  The SynagevaAlexion Merger: Stock and Cash Considerations
04:25PM  Alexion Pharmaceuticals Pays up to Get Synageva BioPharma
07:00AM  Move Over, Elon Musk. CNBC's No. 1 Disruptor This Year is a Biotech Company, Moderna at Forbes
07:00AM  Disruptor 50: No.1 Moderna Therapeutics at CNBC
07:00AM  A hot biotech that may be the next Genentech at CNBC
May-08-15 06:22PM  SYNAGEVA BIOPHARMA CORP. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout PR Newswire
02:17PM  2 reasons we're not in biotech bubble: Pro
12:47PM  Week in Review, May 9 at Financial Times
11:03AM  Jobless Claims Are Driven by Technology: XLK Up and QQQ Gains
09:21AM  Alexion Pharmaceuticals, Inc. (ALXN) in Focus: Stock Jumps 5.1% - Tale of the Tape
May-07-15 04:25PM  Alexion to Buy Synageva for $8.4B: Alexion Down, Synageva Up - Analyst Blog +5.13%
04:03PM  Morgan Stanley: Market's Reaction To Linger For Alexion Pharmaceuticals
03:30PM  Here's What Canaccord Learned After Spending A Day With Synageva's Management
10:59AM  The Lesson From Alexion & Synageva? 'Don't Sleep on M&A' at Barrons.com
09:42AM  How Wedbush Sees The AlexionSynageva Deal
08:50AM  Alexion Pharma upgraded by Nomura
08:30AM  Why These 4 Biotech Stocks Could Be the Next Buyout Targets at 24/7 Wall St.
08:04AM  Is biotech in a bubble?
05:45AM  Fear of a 'Soliris Killer' Might Have Driven Alexion to Overpay for Synageva at TheStreet
12:34AM  PRESS DIGEST- New York Times business news - May 7 Reuters
May-06-15 06:23PM  Biotech blastoff: Synageva up 112% on $8B Alexion deal at USA TODAY -8.03%
06:20PM  Alexion's $8.4 Billion Synageva Buyout Spooks Street at Investor's Business Daily
05:27PM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial S
04:41PM  Rich Synageva M&A premium epitomizes appetite for orphan drugs
04:20PM  Alexion to buy Synageva
03:50PM  Biotech guru does double-take on mega deal at CNBC
03:14PM  Everything you need to know about the $8.4B acquisition of Synageva at bizjournals.com
02:54PM  REUTERS BUSINESS NEWS SCHEDULE AT 1830 GMT/2:30 PM ET
02:40PM  Synageva BioPharma: Another Winning Lottery Ticket For Investors at Forbes
01:59PM  Synageva Biopharma (GEVA) Stock More Than Doubles to 52-Week High on Alexion Acquisition at TheStreet
01:38PM  Alexion Pharmaceuticals (ALXN) Stock Falls After Agreeing to Acquire Synageva Biopharma at TheStreet
01:30PM  Alexion Pharmaceutical's Premium for Synageva Is Fourth-Highest on Record at The Wall Street Journal
01:23PM  Stocks Fall On Yellen Comment; Tesla Firm Ahead Of Earnings at Investor's Business Daily
01:23PM  How to Trade the Market's Most Active Stocks at TheStreet
12:25PM  Alexion & Synageva: A Great Fit? at Barrons.com
12:13PM  Another mega deal in biotech
11:48AM  Alexion Pharma to pay $8.4 billion for Synageva BioPharma
10:48AM  Alexion Buying Synageva For $230 A Share; Stock Slips at Investor's Business Daily
10:30AM  Synageva Shares Soar 116% On Buyout Deal With Alexion Pharmaceuticals
10:28AM  Stocks Fade From Higher Open; Synageva Surges On Buyout News at Investor's Business Daily
10:07AM  Rare disease stocks fly on Alexion acquisition
10:00AM  Huge Buyout Highlights 4 Deutsche Bank Biotech Focus Stocks at 24/7 Wall St.
09:55AM  Alexion Will Buy Synageva for $8.4 Billion
09:43AM  Stocks to Watch: Herbalife, Wendy's and Alexion Pharmaceuticals at The Wall Street Journal
09:43AM  Drugmakers Alexion, Synageva in $8.4 billion deal at USA TODAY
09:30AM  Is Alexion Grossly Overpaying for Synageva? at 24/7 Wall St.
08:45AM  Alexion to buy Synageva for $8.4bn at Financial Times
08:35AM  Alexion Pays Hefty $8.4 Billion to Acquire Synageva, Expand Rare Disease Drug Business at TheStreet
07:30AM  Alexion to buy Synageva in $8.4 billion biotech deal at MarketWatch
06:54AM  Alexion Pharma to buy Synageva BioPharma for $8.4 bln
06:39AM  Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases Business Wire
May-05-15 04:41PM  Researchers Present New Data from Phase 2 Clinical Trial of Eculizumab (SolirisĀ®) in Prevention of Acute Antibody-Mediated Rejection (AMR) in Sensitized Deceased-Donor Kidney Transplant Recipients Business Wire
02:32PM  Sure, the Biotech Sector is Getting Hammered. Here's How to Take Advantage. at Barrons.com
Apr-30-15 11:29PM  Alexion Pharmaceuticals (ALXN) Earnings Analysis: By the Numbers
01:04PM  ALEXION PHARMACEUTICALS INC Financials
Apr-29-15 10:00AM  Alexion to Present at Investor Conferences Business Wire
Apr-27-15 08:30AM  Short Sellers Become More Wary of Big Biotech at 24/7 Wall St.
Apr-26-15 08:14PM  10-Q for Alexion Pharmaceuticals, Inc. at Company Spotlight
Apr-24-15 04:11PM  ALEXION PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
Apr-23-15 07:45PM  Biogen Earnings Preview: What To Look For at Investor's Business Daily
07:43PM  Alexion Pharmaceuticals (ALXN) Earnings Report: Q1 2015 Conference Call Transcript at TheStreet
05:02PM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
04:15PM  Alexion Pharmaceuticals (ALXN) Stock Fell Today on Missed Earnings, Weak Guidance at TheStreet
10:27AM  Alexion Misses Q1 Earnings Estimates, Keeps 2015 Outlook - Analyst Blog
07:55AM  Alexion (ALXN) Misses on Q1 Earnings, Maintains Outlook - Tale of the Tape
07:07AM  Q1 2015 Alexion Pharmaceuticals Inc Earnings Release - Before Market Open
07:04AM  Alexion Reports First Quarter 2015 Results at noodls
06:46AM  Alexion misses 1Q profit forecasts
06:30AM  Alexion Reports First Quarter 2015 Results Business Wire
Apr-22-15 07:31PM  Forget Google: 5 Top Stocks With Earnings Thursday at Investor's Business Daily
Apr-21-15 05:10PM  Will Alexion's (ALXN) Soliris Drive Q1 Earnings Beat? - Analyst Blog
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH and aHUS registry; Phase III clinical trials for the treatment of delayed kidney transplant graft function and myasthenia gravis; and Phase II clinical trials for the treatment of antibody mediated rejection in presensitized kidney transplant patients and neuromyelitis optica. In addition, it develops Asfotase alfa, a targeted enzyme replacement therapy that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1007, a novel humanized antibody in Phase II clinical trials for the treatment of anti-phospholipid syndrome and graft versus host disease; and cPMP (ALXN 1101) that is in Phase II trial for treating metabolic disorders. The company primarily serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BELL LEONARDDirectorJun 18Sale179.6327,8355,000,001922,291Jun 19 07:09 PM
Moriarty John BEVP & General CounselJun 11Sale170.00914155,38032,428Jun 12 06:26 PM
Monnet DominiqueSVP, Chief Marketing OfficerMay 20Sale162.4025641,5748,787May 22 05:30 PM
MACKAY MARTINEVP & Global Head of R&DMay 14Sale160.334,056650,29832,893May 22 05:30 PM
Islam SaqibEVP, Chief Strat & Port. Off.Apr 27Sale181.576,0321,095,23039,868Apr 30 09:45 PM
BELL LEONARDCEOMar 19Sale188.0715,9523,000,093949,426Mar 20 05:02 PM
MACKAY MARTINEVP & Global Head of R&DMar 02Sale180.3437066,72636,949Mar 03 09:13 PM
Sinha VikasEVP & CFOMar 02Sale180.3448787,826167,321Mar 03 09:13 PM
O'Neill JulieEVP. Global OperationsMar 02Sale180.346,5651,183,93222,090Mar 03 09:13 PM
Islam SaqibEVP, Chief Strat & Port. Off.Mar 02Sale180.3422841,11839,432Mar 03 09:12 PM
Moriarty John BEVP & General CounselMar 02Sale180.3428050,49533,342Mar 03 09:13 PM
BELL LEONARDCEOMar 02Sale180.341,230221,818965,378Mar 03 09:11 PM
Hallal DavidChief Operating OfficerMar 02Sale180.34730131,648132,858Mar 03 09:11 PM
Carmichael ClareEVP, Chief HR OfficerMar 02Sale180.34706127,32027,809Mar 03 09:12 PM
MACKAY MARTINEVP & Global Head of R&DFeb 10Sale173.973,897677,95632,219Feb 12 09:07 PM
Monnet DominiqueSVP, Chief Marketing OfficerFeb 10Sale171.1532555,6245,213Feb 12 09:07 PM
O'Neill JulieEVP. Global OperationsFeb 10Sale171.15795136,06423,555Feb 12 09:07 PM
Sinha VikasEVP & CFOFeb 10Sale171.151,985339,733162,708Feb 12 09:08 PM
BELL LEONARDCEOFeb 10Sale171.155,740982,401944,308Feb 12 09:06 PM
Hallal DavidChief Operating OfficerFeb 10Sale171.151,980338,877124,033Feb 12 09:06 PM
Carmichael ClareEVP, Chief HR OfficerFeb 10Sale171.151,490255,01421,670Feb 12 09:06 PM
Islam SaqibEVP, Chief Strat & Port. Off.Feb 10Sale171.151,500256,72534,560Feb 12 09:06 PM
Moriarty John BEVP & General CounselFeb 10Sale171.151,490255,01426,777Feb 12 09:07 PM
Sinha VikasEVP & CFOFeb 09Sale174.182,703470,810164,693Feb 09 08:48 PM
Moriarty John BEVP & General CounselFeb 09Sale174.161,455253,40328,267Feb 09 08:48 PM
BELL LEONARDCEOFeb 09Sale173.988,6601,506,667950,048Feb 09 08:46 PM
Hallal DavidChief Operating OfficerFeb 09Sale173.932,920507,876126,013Feb 09 08:46 PM
Carmichael ClareEVP, Chief HR OfficerFeb 09Sale173.751,665289,29423,160Feb 09 08:47 PM
Hallal DavidChief Operating OfficerFeb 04Sale174.38608106,023117,243Feb 05 08:10 PM
Carmichael ClareEVP, Chief HR OfficerFeb 04Sale174.3520736,09016,065Feb 05 08:09 PM
Sinha VikasEVP & CFOFeb 04Sale174.37676117,874155,706Feb 05 08:10 PM
BELL LEONARDCEOFeb 04Sale174.352,223387,583924,718Feb 05 08:10 PM
BELL LEONARDCEOFeb 03Sale174.253,000522,750926,941Feb 05 08:10 PM
Sinha VikasEVP & CFOFeb 03Sale174.06895155,784156,382Feb 05 08:10 PM
Hallal DavidChief Operating OfficerFeb 03Sale174.02765133,125117,851Feb 05 08:10 PM
Hallal DavidChief Operating OfficerDec 18Sale182.035,4941,000,073113,122Dec 19 04:49 PM
BELL LEONARDCEODec 18Sale182.0313,7352,500,182929,941Dec 19 04:49 PM
BELL LEONARDCEODec 17Option Exercise22.9016,680381,972960,356Dec 19 04:49 PM
BELL LEONARDCEODec 17Sale177.8416,6802,966,315943,676Dec 19 04:49 PM
Brennan David RDirectorDec 15Buy186.9950093,4951,268Dec 16 05:18 PM
Moriarty John BEVP & General CounselDec 11Sale195.533,570698,04220,962Dec 15 06:50 PM
Veneman Ann MDirectorDec 11Sale193.031,235238,3923,447Dec 15 06:50 PM
BELL LEONARDCEODec 09Option Exercise22.9016,665381,629960,341Dec 09 07:37 PM
BELL LEONARDCEODec 09Sale199.9416,6653,332,000943,676Dec 09 07:37 PM
BELL LEONARDCEODec 08Option Exercise21.8159,9341,307,1561,003,610Dec 09 07:37 PM
BELL LEONARDCEODec 08Sale198.8859,93411,919,423943,676Dec 09 07:37 PM
BELL LEONARDCEODec 05Option Exercise17.9856,7211,019,8441,000,397Dec 09 07:37 PM
BELL LEONARDCEODec 05Sale197.1256,72111,181,101943,676Dec 09 07:37 PM
Carmichael ClareSVP, Chief HR OfficerDec 04Option Exercise57.0210,000570,20026,272Dec 08 04:59 PM
Carmichael ClareSVP, Chief HR OfficerDec 04Sale196.2510,0001,962,50016,272Dec 08 04:59 PM
KELLER WILLIAM RDirectorDec 04Sale196.255,000981,2507,276Dec 08 04:59 PM
Sinha VikasEVP & CFODec 03Option Exercise19.1550,000957,400212,770Dec 04 05:20 PM
Sinha VikasEVP & CFODec 03Sale198.3650,0009,918,230162,770Dec 04 05:20 PM
Sinha VikasEVP & CFODec 02Option Exercise17.9825,000449,500187,770Dec 04 05:20 PM
Sinha VikasEVP & CFODec 02Sale200.1625,0005,004,000162,770Dec 04 05:20 PM
BELL LEONARDCEONov 20Sale191.965,2101,000,112943,676Nov 24 05:28 PM
Sinha VikasEVP & CFONov 06Option Exercise17.985,693102,360168,463Nov 10 05:44 PM
Sinha VikasEVP & CFONov 06Sale195.005,6931,110,135162,770Nov 10 05:44 PM
Sinha VikasEVP & CFONov 03Option Exercise17.9630,000538,800192,770Nov 04 06:35 PM
Hallal DavidChief Operating OfficerNov 03Option Exercise20.3930,000611,736148,616Nov 04 06:36 PM
Islam SaqibSVP, Chief Strat & Port. Off.Nov 03Option Exercise89.2328,1252,509,59455,425Nov 04 06:36 PM
MACKAY MARTINEVP & Global Head of R&DNov 03Option Exercise104.869,375983,06333,801Nov 04 06:36 PM
MACKAY MARTINEVP & Global Head of R&DNov 03Sale191.529,3751,795,50024,426Nov 04 06:36 PM
Sinha VikasEVP & CFONov 03Sale190.9930,0005,729,619162,770Nov 04 06:35 PM
Hallal DavidChief Operating OfficerNov 03Sale190.0130,0005,700,287118,616Nov 04 06:36 PM
Islam SaqibSVP, Chief Strat & Port. Off.Nov 03Sale190.5028,1255,357,83127,300Nov 04 06:36 PM
Sinha VikasEVP & CFOOct 31Option Exercise17.9319,307346,186182,077Nov 04 06:35 PM
Sinha VikasEVP & CFOOct 31Sale195.1819,3073,768,340162,770Nov 04 06:35 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerOct 27Option Exercise62.735,550348,140112,418Oct 28 05:41 PM
Moriarty John BSVP & General CounselOct 27Option Exercise92.6510,000926,50034,532Oct 28 05:41 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerOct 27Sale188.585,9101,114,532106,508Oct 28 05:41 PM
Moriarty John BSVP & General CounselOct 27Sale189.4910,0001,894,93724,532Oct 28 05:41 PM
BURNS M MICHELEDirectorOct 17Buy167.32101,673788Dec 08 04:59 PM
Moriarty John BSVP & General CounselOct 06Option Exercise95.6510,000956,50034,532Oct 08 04:55 PM
Moriarty John BSVP & General CounselOct 06Sale179.0010,0001,790,00024,532Oct 08 04:55 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerOct 03Option Exercise42.6610,025427,667116,893Oct 07 08:13 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerOct 03Sale172.4110,0251,728,374106,868Oct 07 08:13 PM
BELL LEONARDCEOSep 26Sale165.1260,0009,906,901948,886Sep 26 05:52 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerSep 24Sale159.507612,122106,868Sep 26 05:53 PM
BELL LEONARDCEOSep 18Sale161.4512,3882,000,0431,008,886Sep 18 05:33 PM
BELL LEONARDCEOSep 16Option Exercise17.6532,047565,6301,053,321Sep 18 05:33 PM
BELL LEONARDCEOSep 16Sale160.2632,0475,136,0051,021,274Sep 18 05:33 PM
BELL LEONARDCEOSep 10Sale165.3812,1992,017,4711,021,274Sep 12 08:59 PM
Carmichael ClareSVP, Chief HR OfficerSep 02Sale169.4630451,51616,272Sep 04 04:34 PM
BELL LEONARDCEOAug 15Option Exercise17.6535,000617,7501,062,186Aug 18 05:46 PM
BELL LEONARDCEOAug 15Sale170.0635,0005,952,1001,027,186Aug 18 05:46 PM
BELL LEONARDCEOAug 14Option Exercise17.6535,000617,7501,062,186Aug 18 05:46 PM
BELL LEONARDCEOAug 14Sale165.9235,0005,807,3661,027,186Aug 18 05:46 PM
BELL LEONARDCEOAug 13Option Exercise17.6524,542433,1661,051,728Aug 13 07:10 PM
BELL LEONARDCEOAug 13Sale162.5224,5423,988,5941,027,186Aug 13 07:10 PM
BELL LEONARDCEOAug 12Option Exercise17.6580,4581,420,0841,107,644Aug 13 07:10 PM
BELL LEONARDCEOAug 12Sale160.1680,45812,885,9101,027,186Aug 13 07:10 PM
BELL LEONARDCEOAug 04Sale157.885,145812,2931,027,186Aug 05 04:55 PM
Hallal DavidEVP, Chief Commercial OfficerAug 04Sale158.001,349213,142118,616Aug 05 04:55 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerAug 04Sale157.421,662261,632106,944Aug 05 04:55 PM
Carmichael ClareSVP, Chief HR OfficerAug 04Sale158.2318429,11416,576Aug 05 04:54 PM
Sinha VikasEVP & CFOAug 04Sale157.821,525240,676162,770Aug 05 04:54 PM
BELL LEONARDCEOJul 30Option Exercise17.6520,489361,6311,052,820Jul 30 05:08 PM
BELL LEONARDCEOJul 30Sale165.6920,4893,394,8331,032,331Jul 30 05:08 PM
BELL LEONARDCEOJul 29Option Exercise17.651,20021,1801,033,531Jul 30 05:08 PM